Benjamin Edwards Inc. Purchases 57,948 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Benjamin Edwards Inc. increased its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 18,454.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 58,262 shares of the company’s stock after acquiring an additional 57,948 shares during the period. Benjamin Edwards Inc.’s holdings in 10x Genomics were worth $1,315,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. First Horizon Advisors Inc. boosted its holdings in shares of 10x Genomics by 74.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company’s stock valued at $37,000 after purchasing an additional 808 shares in the last quarter. KBC Group NV lifted its position in shares of 10x Genomics by 38.8% during the 3rd quarter. KBC Group NV now owns 3,225 shares of the company’s stock worth $73,000 after buying an additional 902 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in 10x Genomics by 134.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,637 shares of the company’s stock valued at $32,000 after buying an additional 939 shares in the last quarter. Blue Trust Inc. grew its position in 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after acquiring an additional 1,025 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in 10x Genomics by 451.8% during the third quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock worth $35,000 after acquiring an additional 1,265 shares in the last quarter. 84.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TXG. Barclays reduced their price target on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Stephens reaffirmed an “overweight” rating and set a $30.00 target price on shares of 10x Genomics in a research note on Thursday, October 10th. UBS Group dropped their price target on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. The Goldman Sachs Group cut their price objective on 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a report on Wednesday, October 30th. Finally, Morgan Stanley lowered their target price on 10x Genomics from $50.00 to $46.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, seven have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.19.

10x Genomics Trading Down 4.8 %

Shares of 10x Genomics stock opened at $15.23 on Friday. The business has a 50-day moving average price of $16.53 and a two-hundred day moving average price of $19.35. 10x Genomics, Inc. has a 1-year low of $12.95 and a 1-year high of $57.90. The company has a market cap of $1.84 billion, a P/E ratio of -9.95 and a beta of 1.84.

10x Genomics (NASDAQ:TXG) last released its earnings results on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.04. The business had revenue of $151.65 million during the quarter, compared to analysts’ expectations of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The firm’s revenue was down 1.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.51) earnings per share. Equities research analysts forecast that 10x Genomics, Inc. will post -1.4 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.